Elevate Healthcare and Recordati Rare Diseases Inc.
SYLVANT Can Open the Door
SYLVANT is the only FDA-approved therapy for idiopathic multicentric Castleman disease (iMCD) that targets the underlying cytokine storm and can help deliver sustained symptomatic relief and durable tumor response. iMCD can present with a wide range of symptoms. The cage symbolizes the symptoms of iMCD that may leave a patient feeling trapped and how SYLVANT can help open the door to a patient’s life through treatment.
ELEVATE HEALTHCARE TEAM MEMBERS:
Lorna Weir Managing Partner
Taylor Myers-Ackerman Group Account Supervisor, Client Engagement
Layne Musser Assistant Manager, Client Engagement
Jenna Logan Senior Project Manager
Barry Schmader Chief Creative Officer
Tara Powers VP, Creative Director, Art
Jen Brog Art Supervisor
Rachel Underwood, PhD Medical Writer
Dave Marks, PhD, MSc, VP Medical Director
RECORDATI RARE DISEASES INC. TEAM MEMBERS:
Jeroen Commissaris VP Commercial Operations, U.S. Oncology
Sergio Cuello Head of Marketing, U.S. Oncology
Cameron Duvall Senior Product Manager, U.S. Oncology
